Galecto Inc (NAS:GLTO)

$ 0.5404 0.0253 (4.91%) Market Cap: 14.65 Mil Enterprise Value: -13.05 Mil PE Ratio: 0 PB Ratio: 0.52 GF Score: 38/100

Galecto Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Galecto Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Galecto Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Galecto Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Galecto Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2022
Galecto Inc Corporate Call-Topline data From the Company Phase 1b/2a GULLIVER-2 Trial for liver cirrhosis Transcript
Nov 08, 2022
Galecto Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Galecto Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2022
Galecto Inc at LifeSci Partners Immunology & Inflammation Symposium Transcript
May 11, 2022

Galecto Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 13, 2023 / 01:20PM GMT

Release Date Price: $1.97 (+15.88%)

Transcript 10-K

Jay Olson

Oppenheimer & Co. Inc. - Analyst

Hello, everyone, and welcome to Oppenheimer's 33rd Annual Healthcare Conference. I'm Jay Olson, one of the biotechnology analysts at Oppenheimer. And I want to thank you all for joining us. It's my pleasure to welcome Galecto to our conference, and it's an honor to introduce Hans Schambye, the Chief Executive Officer. Thank you for joining us today, Hans. It's a pleasure to catch up with you. And with that, I'll turn it over to you.

Hans Schambye

Galecto, Inc. - CEO

Thanks a lot, Jay. Always a pleasure to see you and very happy to be presenting the Galecto today.

Jay Olson

Oppenheimer & Co. Inc. - Analyst

Our pleasure.

Hans Schambye

Galecto, Inc. - CEO

Galecto is a company that is developing first-in-class, small-molecule, antifibrotic and anticancer agents. I'll be making forward-looking statements, and you can find this statement on our website. In Galecto, we are working to create a world where patients suffering

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.